Oxford BioMedica - Validation achieved, growth expected
Following the commercial launch in 2017 of partner Novartis’s CAR-T Kymriah (in r/r paediatric ALL), Oxford BioMedica (OXB) has become one of a...
98 Views
Oxford BioMedica - LentiVector platform expanding into haemophilia
Oxford BioMedica (OXB) has announced a collaboration and licence agreement with Bioverativ to develop gene therapy products for the treatment of...
87 Views
Kymriah approved - royalties to OXB assured
Kymriah (tisagenlecleucel/CTL019), for which Oxford BioMedica (OXB) provides the key lentiviral vector component, has been approved by the FDA for...
128 Views
CTL019 approval likely in pALL, ad-com positive
With a probable approval for Novartis’s CTL019 (tisagenlecleucel) (OXB manufacture a key component) in both paediatric ALL and DLBCL on the...
107 Views
Lentiviral vector supply for CTL019 driving revenue growth
Oxford BioMedica has today announced a significant agreement with Novartis for the ongoing commercial and clinical supply of lentiviral vectors...
83 Views